Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
Positive Phase III results from the SANOVO and SAFFRON studies with Orpathys raise several sequencing and usage considerations.
Read Full Article
Pharma Tech
Transitioning from lab bench to GMP: What research scientists should know about manual aseptic filling
When it’s time to look for a fill-finish CDMO, the transition to GMP filling is not just a scale issue — it’s a regulatory, technical, and operational shift.
Read Full Article
Pharma Tech
Lunit and Summit to evaluate pathology platform for tumour analysis
Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing the tumour microenvironment across immuno-oncology programmes evaluating ivonescimab.
Read Full Article
Pharma Tech
Pathos AI completes $237m Series E round to expand oncology pipeline
Pathos AI has secured $237m in a Series E round to expand its clinical oncology pipeline and scale its AI drug development platform.
Read Full Article
Pharma Tech
UK biotech poised for record VC year after maintaining recovery momentum
British biotech generally raised more across public and private markets in Q3 2026, despite an overall downturn in the flow of VC more generally into the UK.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
PharmaShots
Oct 27, 2026, 5:56 AM
Sumitomo Pharma America’s Enzomenib (DSP-5336) Receives the US FDA’s Breakthrough Therapy Designation for R/R KMT2A-Rearranged Acute Leukemia
Shots: The US FDA has granted BTD to Sumitomo Pharma America’s enzomenib (DSP-5336) for treating pts with R/R acute leukemia with KMT2A rearrangement Enzomenib is being evaluated as monotx in the registrational P-II (Horizen-1) study in R/R acute leukemia with KMT2A rearrangement or NPM1 mutation & in combination with SoC regimens in newly diagnosed &… The post Sumitomo Pharma America’s Enzomenib (DSP-5336) Receives the US FDA’s Breakthrough Therapy Designation for R/R KMT2A-Rearranged Acute Leukemia appeared first on PharmaShots.
PharmaShots
Oct 27, 2026, 5:53 AM
Regeneron Reports Longer-Term P-III (C-POST) Trial Data of Adjuvant Libtayo (Cemiplimab) for High-Risk Cutaneous Squamous Cell Carcinoma at ESMO 2026
Shots: Regeneron reported ~4yr follow-up data from the P-III (C-POST) trial of Libtayo (cemiplimab) vs PBO as adjuvant treatment in pts (n=415) with CSCC at high risk of recurrence after surgery & radiation; presented as a late-breaking rapid oral at ESMO 2026 At a median follow-up of 44mos, Libtayo showed a 37% reduction in risk… The post Regeneron Reports Longer-Term P-III (C-POST) Trial Data of Adjuvant Libtayo (Cemiplimab) for High-Risk Cutaneous Squamous Cell Carcinoma at ESMO 2026 appeared first on PharmaShots.
PharmaShots
Oct 27, 2026, 5:27 AM
BioNTech and DualityBio Report Topline P-III (DYNASTY-Breast02) Trial Results of Trastuzumab Pamirtecan for HR+/HER2-Low Metastatic Breast Cancer
Shots: BioNTech & DualityBio reported topline P-III (DYNASTY-Breast02) results of trastuzumab pamirtecan (BNT323/DB-1303) vs investigator’s choice CT in CT-naïve pts (n=541) with HR+/HER2-low mBC who progressed on ET The trial met its 1EP with a statistically significant but modest PFS improvement, while OS data were immature at the interim analysis; ILD rates were higher than… The post BioNTech and DualityBio Report Topline P-III (DYNASTY-Breast02) Trial Results of Trastuzumab Pamirtecan for HR+/HER2-Low Metastatic Breast Cancer appeared first on PharmaShots.
PharmaShots
Oct 27, 2026, 4:54 AM
Bayer Reports P-III (DASL-HiCaP) Trial Data of Nubeqa (Darolutamide) + ADT and Radiation Therapy for High-Risk Prostate Cancer at ESMO 2026
Shots: Bayer reported interim P-III (DASL-HiCaP) data of Nubeqa (darolutamide, 600mg BID) vs PBO, each + ADT & locoregional RT for 96wks, in pts (n=1,106) with prostate cancer at high risk of recurrence; presented as LBA4 at ESMO 2026 Presidential Symposium At a median follow-up of 3.8yrs, Nubeqa reduced risk of metastasis or death by… The post Bayer Reports P-III (DASL-HiCaP) Trial Data of Nubeqa (Darolutamide) + ADT and Radiation Therapy for High-Risk Prostate Cancer at ESMO 2026 appeared first on PharmaShots.
ET Pharma
Oct 27, 2026, 1:39 AM
US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk
US District Judge Zahid Quraishi in Trenton, New Jersey, said Novo Nordisk did not deserve a preliminary injunction, having failed to show that Eli Lilly's ads threatened sales, undermined its goodwill, or caused lasting damage to its clinical reputation.
Pharma Tech
Oct 26, 2026, 3:52 PM
ESMO26: SANOVO data backs 1L Orpathys use in NSCLC subgroup, but AEs temper reaction
Positive Phase III results from the SANOVO and SAFFRON studies with Orpathys raise several sequencing and usage considerations.
News
Latest industry coverage
Google News
Oct 27, 2026, 7:35 AM
Novartis back on track for growth in third quarter - SWI swissinfo.ch
Novartis back on track for growth in third quarter SWI swissinfo.ch
Google News
Oct 27, 2026, 7:31 AM
Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree - WSJ
Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree WSJ
Google News
Oct 27, 2026, 7:00 AM
‘Why do we value a Mars bar more than life-saving medicine?’ Sandoz CEO calls for level playing field with cheap Chinese antibiotics - Fortune
‘Why do we value a Mars bar more than life-saving medicine?’ Sandoz CEO calls for level playing field with cheap Chinese antibiotics Fortune
Google News
Oct 27, 2026, 6:46 AM
Drug Manufacturing Plant Setup Cost in India - IMARC Group
Drug Manufacturing Plant Setup Cost in India IMARC Group
Google News
Oct 27, 2026, 6:32 AM
The In Silico Drug Discovery Market is Expected to Grow Rapidly at a 13.1% CAGR Through 2030 - EIN Presswire
The In Silico Drug Discovery Market is Expected to Grow Rapidly at a 13.1% CAGR Through 2030 EIN Presswire
Google News
Oct 27, 2026, 6:32 AM
Nanocarriers Market Analysis Report Examining Demand Patterns and Competitive Landscape - EIN News
Nanocarriers Market Analysis Report Examining Demand Patterns and Competitive Landscape EIN News
Google News
Oct 27, 2026, 6:06 AM
Biopharmaceutical company CSL shifts strategy with sights set on expansion - China Daily
Biopharmaceutical company CSL shifts strategy with sights set on expansion China Daily
Google News
Oct 27, 2026, 5:31 AM
Why Biotech Needs Partners—and an Informed Public - TechNode
Why Biotech Needs Partners—and an Informed Public TechNode
Google News
Oct 27, 2026, 5:00 AM
Can French drugmaker Sanofi fix its pipeline? - Financial Times
Can French drugmaker Sanofi fix its pipeline? Financial Times
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer